177 related articles for article (PubMed ID: 36209277)
21. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
[TBL] [Abstract][Full Text] [Related]
22. Multimodal data analysis reveals that pancreatobiliary-type ampullary adenocarcinoma resembles pancreatic adenocarcinoma and differs from cholangiocarcinoma.
Cheng J; Mao Y; Hong W; Hu W; Shu P; Huang K; Yu J; Jiang M; Li L; Wang W; Ni D; Li S
J Transl Med; 2022 Jun; 20(1):272. PubMed ID: 35705951
[TBL] [Abstract][Full Text] [Related]
23. Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway.
Hu X; Zhang R; Yao J; Mu B; Zhao C
Mol Med Rep; 2023 Jan; 27(1):. PubMed ID: 36367161
[TBL] [Abstract][Full Text] [Related]
24. NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma.
Ramakrishnan G; Parajuli P; Singh P; Friend C; Hurwitz E; Prunier C; Razzaque MS; Xu K; Atfi A
Cell Rep; 2022 Nov; 41(6):111623. PubMed ID: 36351408
[TBL] [Abstract][Full Text] [Related]
25. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
[TBL] [Abstract][Full Text] [Related]
26. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
[TBL] [Abstract][Full Text] [Related]
27. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
28. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia.
Shi G; DiRenzo D; Qu C; Barney D; Miley D; Konieczny SF
Oncogene; 2013 Apr; 32(15):1950-8. PubMed ID: 22665051
[TBL] [Abstract][Full Text] [Related]
29. Characterization of KRAS Mutation in Acinar and Langerhans Islet Cells of Patients With Pancreatic Ductal Adenocarcinoma.
Wang Z; Zhang C; Nagee K; Mohammadi A; Monteiro C
Pancreas; 2016 Mar; 45(3):337-41. PubMed ID: 26474433
[TBL] [Abstract][Full Text] [Related]
30. An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma.
Zhang M; Huang Y; Pan J; Sang C; Lin Y; Dong L; Shen X; Wu Y; Song G; Ji S; Liu F; Wang M; Zheng Y; Zhang S; Wang Z; Ren J; Gao D; Zhou J; Fan J; Wei W; Lin J; Gao Q
Cancer Discov; 2023 Oct; 13(10):2248-2269. PubMed ID: 37486241
[TBL] [Abstract][Full Text] [Related]
31. Mutations of KRAS and TP53 in a minor proportion of Opisthorchis viverrini-associated cholangiocarcinomas in a hamster model.
Tangkawattana S; Kaewkes S; Pairojkul C; Tangkawattana P; Sripa B
Asian Pac J Cancer Prev; 2008; 9(1):101-6. PubMed ID: 18439086
[TBL] [Abstract][Full Text] [Related]
32. Identification of
Thein KZ; Biter AB; Banks KC; Duda AW; Saam J; Roszik J; Janku F; Skoulidis F; Heymach JV; Kopetz S; Meric-Bernstam F; Hong DS
JCO Precis Oncol; 2022 Jul; 6():e2100547. PubMed ID: 35862868
[TBL] [Abstract][Full Text] [Related]
33. Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
Kendall T; Verheij J; Gaudio E; Evert M; Guido M; Goeppert B; Carpino G
Liver Int; 2019 May; 39 Suppl 1():7-18. PubMed ID: 30882996
[TBL] [Abstract][Full Text] [Related]
34. Epithelial Nr5a2 heterozygosity cooperates with mutant Kras in the development of pancreatic cystic lesions.
Cobo I; Iglesias M; Flández M; Verbeke C; Del Pozo N; Llorente M; Lawlor R; Luchini C; Rusev B; Scarpa A; Real FX
J Pathol; 2021 Feb; 253(2):174-185. PubMed ID: 33079429
[TBL] [Abstract][Full Text] [Related]
35. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
[TBL] [Abstract][Full Text] [Related]
36. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
[TBL] [Abstract][Full Text] [Related]
37. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
[TBL] [Abstract][Full Text] [Related]
38. The cellular origins of cancer with particular reference to the gastrointestinal tract.
Alison MR
Int J Exp Pathol; 2020 Oct; 101(5):132-151. PubMed ID: 32794627
[TBL] [Abstract][Full Text] [Related]
39. De novo somatic mutations and KRAS amplification are associated with cholangiocarcinoma in a patient with a history of choledochal cyst.
Schwab ME; Song H; Mattis A; Phelps A; Vu LT; Huang FW; Nijagal A
J Pediatr Surg; 2020 Dec; 55(12):2657-2661. PubMed ID: 32295706
[TBL] [Abstract][Full Text] [Related]
40. ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis.
Wang L; Yang H; Zamperone A; Diolaiti D; Palmbos PL; Abel EV; Purohit V; Dolgalev I; Rhim AD; Ljungman M; Hadju CH; Halbrook CJ; Bar-Sagi D; di Magliano MP; Crawford HC; Simeone DM
Genes Dev; 2019 Jun; 33(11-12):641-655. PubMed ID: 31048544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
